HCPCS Level IIdrugActive
J2281
Inj moxifloxacin (fres kabi)
BETOS: O1E
Effective: 2024-07-01
Referenced in 1 policies
Description
Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Moxifloxacin HCl
Manufacturer
FreseniUS Kabi USA, LLC
HCPCS Dosage
100 MG
Billing Units
4.0000
1
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.